

Exchange Formulary Changes

Drug/Class	Effective Date	Overview
Prevymis pellet pak	4/1/2025	Adding to formulary with PA
Lumakras	4/1/2025	Adding new metastatic colorectal cancer (mCRC) indication
Calquence tab	4/1/2025	Adding new indication in combination with bendamustine & rituximab for patients with previously untreated mantle cell lymphoma (MCL)
Cimzia	4/1/2025	Updating step through criteria for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred option
Kevzara	4/1/2025	Updating step through criteria for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) - removing adalimumab + tocilizumab pathway; adding tocilizumab to preferred agents
Olumiant	4/1/2025	Updating rheumatoid arthritis (RA) step through criteria - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred agent
Orencia	4/1/2025	Updating rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA) step through criteria - removing adalimumab + tocilizumab pathway; adding tocilizumab as preferred option
Tyenne	4/1/2025	Moving tocilizumab into preferred positioning for rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA)
Voranigo	4/1/2025	Adding to formulary with PA
Yorvipath	4/1/2025	Adding to formulary with PA
Ohtuvayre	4/1/2025	Adding to formulary with PA
Iqirvo	4/1/2025	Adding to formulary with PA
Livdelzi	4/1/2025	Adding to formulary with PA
Nemluvio	4/1/2025	Adding to formulary with PA
Ebglyss	4/1/2025	Adding to formulary with PA
Yesintek	4/1/2025	Adding to formulary with PA
Steqeyma	4/1/2025	Adding to formulary with PA
Dupixent	4/1/2025	Updating criteria for prurigo nodularis
Cimzia	4/1/2025	Adding ustekinumab biosimilars
Entyvio SC	4/1/2025	Adding ustekinumab biosimilars
Orencia	4/1/2025	Adding ustekinumab biosimilars
Spevigo SC	4/1/2025	Adding ustekinumab biosimilars
Zeposia	4/1/2025	Adding ustekinumab biosimilars